Details of the Drug

General Information of Drug (ID: DMKXJZ7)

Drug Name

Suprofen

Synonyms

Maldocil; Masterfen; Profenal; Srendam; Sulproltin; Suprocil; Suprofene; Suprofenum; Suprol; Sutoprofen; R 25061; R25061; TN 762; TN762; Profenal (TN); R-25061; Suprofene [INN-French]; Suprofenum [INN-Latin]; TN-762; TYN-762P; P-2-Thenoylhydratropic acid; R-25,061; Suprofen (JAN/USP/INN); Suprofen [USAN:BAN:INN:JAN]; Alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (+-)-2-(p-(2-Thenoyl)phenyl)propionic acid; (-)-alpha-Methyl-4-(2-thienylcarbonyl)benzeneacetic acid; (R)-(Thien-2-ylcarbonyl)propionic acid; (S)-2-(4-(Thien-2-ylcarbonyl)phenyl)butyric acid; 2-(4-(2-Thenoyl)phenyl)propionsaeure; 2-(4-(2-Thienylcarbonyl)phenyl)propanoic acid; 2-[4-(thiophen-2-ylcarbonyl)phenyl]propanoic acid; 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid; 4-(2-Thenoyl)hydratropsaeure

Indication

Disease Entry	ICD 11	Status	REF
Miosis	LA11.62	Approved	[1]

Therapeutic Class

Antiinflammatory Agents

Affected Organisms

Humans and other mammals

ATC Code

M01AE07: Suprofen

M01AE: Propionic acid derivatives

M01A: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS

M01: ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS

M: MUSCULO-SKELETAL SYSTEM

Drug Type

Small molecular drug

Structure

3D MOL

2D MOL

#Ro5 Violations (Lipinski): 0

Molecular Weight (mw)

260.31

Logarithm of the Partition Coefficient (xlogp)

3.3

Rotatable Bond Count (rotbonds)

Hydrogen Bond Donor Count (hbonddonor)

Hydrogen Bond Acceptor Count (hbondacc)

ADMET Property

Bioavailability: 92% of drug becomes completely available to its intended biological destination(s) [2]
Clearance: The drug present in the plasma can be removed from the body at the rate of 0.76 mL/min/kg [3]
Half-life: The concentration or amount of drug in body reduced by one-half in 2.1 hours [3]
Metabolism: The drug is metabolized via the hepatic []
MRTD: The Maximum Recommended Therapeutic Dose (MRTD) of drug that ensured maximising efficacy and moderate side effect is 65.8555 micromolar/kg/day [4]
Unbound Fraction: The unbound fraction of drug in plasma is 0.006% [3]
Vd: Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 0.04 L/kg [3]

Chemical Identifiers

Formula: C14H12O3S
IUPAC Name: 2-[4-(thiophene-2-carbonyl)phenyl]propanoic acid
Canonical SMILES: CC(C1=CC=C(C=C1)C(=O)C2=CC=CS2)C(=O)O
InChI: InChI=1S/C14H12O3S/c1-9(14(16)17)10-4-6-11(7-5-10)13(15)12-3-2-8-18-12/h2-9H,1H3,(H,16,17)
InChIKey: MDKGKXOCJGEUJW-UHFFFAOYSA-N

Cross-matching ID

PubChem CID: 5359
ChEBI ID: CHEMBL956
CAS Number: 40828-46-4
UNII: 988GU2F9PE
DrugBank ID: DB00870
TTD ID: D07BPS
INTEDE ID: DR1520

Drug-Molecule Activity Atlas (DMA)^NEW

Click to Jump to the Detailed DMA Information of This Drug

Drug Pharmacogenomic Perturbation (DPP)^NEW

Click to Jump to the Detailed DPP Information of This Drug

Drug ADMET Endpoint Profile (DAE)^NEW

Click to Jump to the Detailed DAE Information of This Drug

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Prostaglandin G/H synthase 1 (COX-1)	TT8NGED	PGH1_HUMAN	Inhibitor	[5]

Drug-Metabolizing Enzyme (DME)

DME Name	DME ID	UniProt ID	MOA	REF
Cytochrome P450 2C9 (CYP2C9)_{Main DME}	DE5IED8	CP2C9_HUMAN	Substrate	[6]
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DEYGVN4	UD11_HUMAN	Substrate	[7]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Dehydrogenase/reductase SDR family member 11 (DHRS11)	OTU3J0ZL	DHR11_HUMAN	Gene/Protein Processing	[8]

Molecular Interaction Atlas (MIA)

MIA Detail

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Miosis

ICD Disease Classification

LA11.62

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
Prostaglandin G/H synthase 1 (COX-1)	DTT	PTGS1	3.97E-03	0.16	0.43
UDP-glucuronosyltransferase 1A1 (UGT1A1)	DME	UGT1A1	1.10E-01	-5.91E-02	-3.60E-01
Cytochrome P450 2C9 (CYP2C9)	DME	CYP2C9	1.90E-01	-9.81E-03	-5.96E-02

Molecular Expression Atlas (MEA)

MEA Detail

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Suprofen (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Inotersen	DMJ93CT	Moderate	Increased risk of bleeding by the combination of Suprofen and Inotersen.	Amyloidosis [5D00]	[9]
Cilostazol	DMZMSCT	Moderate	Increased risk of bleeding by the combination of Suprofen and Cilostazol.	Arterial occlusive disease [BD40]	[9]
Anisindione	DM2C48U	Moderate	Increased risk of bleeding by the combination of Suprofen and Anisindione.	Coagulation defect [3B10]	[9]
Regorafenib	DMHSY1I	Moderate	Increased risk of bleeding by the combination of Suprofen and Regorafenib.	Colorectal cancer [2B91]	[9]
Ardeparin	DMYRX8B	Moderate	Increased risk of bleeding by the combination of Suprofen and Ardeparin.	Coronary thrombosis [BA43]	[9]
Danaparoid	DM6CLBN	Moderate	Increased risk of bleeding by the combination of Suprofen and Danaparoid.	Deep vein thrombosis [BD71]	[9]
Rivaroxaban	DMQMBZ1	Moderate	Increased risk of bleeding by the combination of Suprofen and Rivaroxaban.	Deep vein thrombosis [BD71]	[9]
Tazemetostat	DMWP1BH	Moderate	Increased risk of bleeding by the combination of Suprofen and Tazemetostat.	Follicular lymphoma [2A80]	[9]
Avapritinib	DMK2GZX	Moderate	Increased risk of bleeding by the combination of Suprofen and Avapritinib.	Gastrointestinal stromal tumour [2B5B]	[9]
Dipyridamole	DMXY30O	Moderate	Increased risk of bleeding by the combination of Suprofen and Dipyridamole.	Hypertension [BA00-BA04]	[9]
PF-06463922	DMKM7EW	Moderate	Increased metabolism of Suprofen caused by PF-06463922 mediated induction of CYP450 enzyme.	Lung cancer [2C25]	[10]
Acalabrutinib	DM7GCVW	Moderate	Increased risk of bleeding by the combination of Suprofen and Acalabrutinib.	Mature B-cell lymphoma [2A85]	[9]
Ibrutinib	DMHZCPO	Moderate	Increased risk of bleeding by the combination of Suprofen and Ibrutinib.	Mature B-cell lymphoma [2A85]	[9]
Ponatinib	DMYGJQO	Moderate	Increased risk of bleeding by the combination of Suprofen and Ponatinib.	Mature B-cell lymphoma [2A85]	[9]
Panobinostat	DM58WKG	Moderate	Increased risk of bleeding by the combination of Suprofen and Panobinostat.	Multiple myeloma [2A83]	[9]
Ruxolitinib	DM7Q98D	Moderate	Increased risk of bleeding by the combination of Suprofen and Ruxolitinib.	Myeloproliferative neoplasm [2A20]	[9]
Dasatinib	DMJV2EK	Moderate	Increased risk of bleeding by the combination of Suprofen and Dasatinib.	Myeloproliferative neoplasm [2A20]	[9]
Prasugrel	DM7MT6E	Moderate	Increased risk of bleeding by the combination of Suprofen and Prasugrel.	Myocardial infarction [BA41-BA43]	[9]
Vorapaxar	DMA16BR	Moderate	Increased risk of bleeding by the combination of Suprofen and Vorapaxar.	Myocardial infarction [BA41-BA43]	[9]
Rucaparib	DM9PVX8	Moderate	Decreased metabolism of Suprofen caused by Rucaparib mediated inhibition of CYP450 enzyme.	Ovarian cancer [2C73]	[11]
Epoprostenol	DMUTYR2	Moderate	Increased risk of bleeding by the combination of Suprofen and Epoprostenol.	Pulmonary hypertension [BB01]	[9]
Iloprost	DMVPZBE	Moderate	Increased risk of bleeding by the combination of Suprofen and Iloprost.	Pulmonary hypertension [BB01]	[9]
Plicamycin	DM7C8YV	Moderate	Increased risk of bleeding by the combination of Suprofen and Plicamycin.	Testicular cancer [2C80]	[9]
Cangrelor	DM8JRH0	Moderate	Increased risk of bleeding by the combination of Suprofen and Cangrelor.	Thrombosis [DB61-GB90]	[9]
Brilinta	DMBR01X	Moderate	Increased risk of bleeding by the combination of Suprofen and Brilinta.	Thrombosis [DB61-GB90]	[9]
Cabozantinib	DMIYDT4	Moderate	Increased risk of bleeding by the combination of Suprofen and Cabozantinib.	Thyroid cancer [2D10]	[9]


⏷ Show the Full List of 26 DDI Information of This Drug

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7298).
2	Critical Evaluation of Human Oral Bioavailability for Pharmaceutical Drugs by Using Various Cheminformatics Approaches
3	Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4	Estimating the safe starting dose in phase I clinical trials and no observed effect level based on QSAR modeling of the human maximum recommended daily dose
5	Differential binding mode of diverse cyclooxygenase inhibitors. J Mol Graph Model. 2002 Mar;20(5):359-71.
6	Mechanism-based inactivation of human recombinant P450 2C9 by the nonsteroidal anti-inflammatory drug suprofen. Drug Metab Dispos. 2003 Nov;31(11):1369-77.
7	Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
8	Rabbit dehydrogenase/reductase SDR family member 11 (DHRS11): Its identity with acetohexamide reductase with broad substrate specificity and inhibitor sensitivity, different from human DHRS11. Chem Biol Interact. 2019 May 25;305:12-20. doi: 10.1016/j.cbi.2019.03.026. Epub 2019 Mar 26.
9	Product Information. Acular (ketorolac). Allergan Inc, Irvine, CA.
10	Cerner Multum, Inc. "Australian Product Information.".
11	Product Information. Accolate (zafirlukast). Zeneca Pharmaceuticals, Wilmington, DE.